- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Selumetinib gets Breakthrough Therapy Designation
AnnouncementREG - AstraZeneca PLC - Results of Placing
AnnouncementREG - AstraZeneca PLC - AZ and Daiichi Sankyo enter collaboration in novel
AnnouncementREG - AstraZeneca PLC - Proposed placing of new ordinary shares
AnnouncementREG - AstraZeneca PLC - Forxiga approved in Japan for type-1 diabetes
AnnouncementREG - AstraZeneca PLC - Forxiga approved in Europe for type-1 diabetes
AnnouncementREG - AstraZeneca PLC - US FDA grants saracatinib ODD for IPF
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - Circassia Pharma Plc AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Lynparza receives positive EU CHMP opinion
AnnouncementREG - AstraZeneca PLC - Lynparza significantly delayed disease progression
AnnouncementREG - AstraZeneca PLC - Brilinta's PhIII THEMIS trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - AstraZeneca Full-Year and Q4 2018 Results
AnnouncementREG - AstraZeneca PLC - US FDA grants Fasenra Orphan Drug Designation
AnnouncementREG - AstraZeneca PLC - US FDA grants Breakthrough Therapy Designation
Announcement